IGC Pharma Announces Interim Results For IGC-AD1 In Reducing Alzheimer's Agitation; Results Indicate That IGC-AD1 Clinically Reduced Agitation Compared To Placebo
IGC Pharma Announces Interim Results For IGC-AD1 In Reducing Alzheimer's Agitation; Results Indicate That IGC-AD1 Clinically Reduced Agitation Compared To Placebo
IGC Pharma 公佈 IGC-AD1 在減少阿爾茨海默氏症激動方面的中期業績；結果表明，與安慰劑相比，IGC-AD1 在臨床上減少了激動
IGC Pharma Announces Interim Results For IGC-AD1 In Reducing Alzheimer's Agitation; Results Indicate That IGC-AD1 Clinically Reduced Agitation Compared To Placebo
IGC Pharma 公佈 IGC-AD1 在減少阿爾茨海默氏症激動方面的中期業績；結果表明，與安慰劑相比，IGC-AD1 在臨床上減少了激動
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。